Study of T-cell responses points toward more durable coronavirus vaccines
Researchers investigated why COVID-19 infections vary so widely by focusing on CD8+ T cells and human leukocyte antigen types. They compared blood samples from 42 HLA-A2-positive patients collected in 2020 before vaccines were available. The work aims to inform treatments and vaccines that produce long-lasting immune protection.
Researchers examined blood from 42 HLA-A2-positive individuals, collected in 2020 before vaccines existed. They analyzed 8,402 T cells reactive to SARS-CoV-2. Mild cases showed more CD8+ killer T cells, with broad attacks lasting up to four months. Severe cases showed dysfunctional T-cell forms, suggesting a weakened immune response.
Many viral targets recognized by these T cells remain largely stable across variants. Because those targets are often internal rather than surface proteins, they may face less mutation pressure than antibody targets. The study, published in iScience, used a controlled HLA-matched comparison to reduce immune-system variability.
This research may inform future COVID-19 vaccine design, potentially helping people at risk of severe disease by guiding shots that elicit longer-lasting T-cell protection. It could also aid clinicians in understanding why outcomes differ among infected patients. Because findings come from pre-vaccine samples and a specific HLA group, broader benefits remain uncertain until confirmed in larger, diverse populations.